Courtney Clement, APRN
Family · Marrero, LANPI 1225558976
Payments from drug & device makers
Across 228 payments — averaging $36.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Amgen$730
- Johnson & Johnson$656
- Novartis$569
- Esperion Therapeutics, Inc.$491
- Novo Nordisk$480
- plus $4K from 32 others
What the payments were for
- Food & beverage$8,318100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 9 | $1,163 |
| Amgen | 19 | $730 |
| Johnson & Johnson(2 entities) | 17 | $656 |
| Novartis | 46 | $569 |
| Esperion Therapeutics, Inc. | 17 | $491 |
| Novo Nordisk | 8 | $480 |
| Edwards Lifesciences | 7 | $439 |
| E.r. Squibb & Sons, L.L.C. | 16 | $388 |
| Merck | 22 | $377 |
| Teva Pharmaceuticals USA, Inc. | 2 | $238 |
| Boston Scientific | 9 | $216 |
| AbbVie | 2 | $216 |
| Lilly USA, LLC | 2 | $203 |
| Abbott | 4 | $185 |
| Inspire Medical Systems, Inc. | 1 | $167 |
| Boehringer Ingelheim | 9 | $163 |
| Madrigal Pharmaceuticals | 1 | $147 |
| Impulse Dynamics (USA) Inc. | 2 | $144 |
| AstraZeneca(2 entities) | 2 | $128 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Xeris Pharmaceuticals, Inc. | 1 | $122 |
| Sanofi | 1 | $122 |
| Neurocrine Biosciences, Inc. | 1 | $104 |
| UCB, Inc. | 1 | $96 |
| Alnylam Pharmaceuticals Inc. | 2 | $91 |
| Atricure, Inc. | 3 | $79 |
| Scpharmaceuticals Inc. | 3 | $65 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $61 |
| Exact Sciences | 1 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Baxter Healthcare | 1 | $42 |
| Amarin Pharma, Inc. | 2 | $39 |
| Philips North America LLC | 2 | $36 |
| Bayer | 2 | $35 |
| Abiomed | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$484
- LINQ II$318
- COBALT DR MRI SURESCAN$303
- Micra$297
- OPTIMIZER$246
- Wegovy$246
- Austedo XR$238
- Inspire Upper Airway Stimulation System$167
- REZDIFFRA$147
- FreeStyle Libre 2$128
- Reveal LINQ$126
- GEMTESA$125
- NEXLIZET$125
- NEXLETOL$125
- Ozempic$125
- CAMZYOS$125
- XARELTO$124
- GVOKE HYPOPEN$122
- FABRAZYME$122
- LINZESS$118
How this compares
$8,318 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 396 | $300,065 |
| Repatha SureclickEvolocumab | 191 | $136,597 |
| XareltoRivaroxaban | 144 | $112,685 |
| EntrestoSacubitril/Valsartan | 105 | $90,820 |
| Praluent PenAlirocumab | 63 | $46,460 |
| NexletolBempedoic Acid | 82 | $39,510 |
| JardianceEmpagliflozin | 39 | $25,498 |
| BrilintaTicagrelor | 48 | $21,347 |
| VascepaIcosapent Ethyl | 25 | $18,339 |
| NexlizetBempedoic Acid/Ezetimibe | 26 | $17,298 |
| Ranolazine ErRanolazine | 121 | $11,078 |
| VerquvoVericiguat | 11 | $7,451 |
| Metoprolol Succinate | 585 | $6,582 |
| ZypitamagPitavastatin Magnesium | 13 | $4,597 |
| Rosuvastatin Calcium | 461 | $3,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $300,065396 claims |
| Johnson & JohnsonXarelto | $656 | $112,685144 claims |
| NovartisEntresto | $569 | $90,820105 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $491 | $56,808108 claims |
| Boehringer IngelheimJardiance | $163 | $25,49839 claims |
| AstraZenecaBrilinta | $128 | $21,34748 claims |
| MerckVerquvo | $377 | $7,45111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Marrero
- Sharon JacksonMarrero$13K
- Jolie MontreuilMarrero$13K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.